Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and it has a robust pipeline of follow-on products in both pre-clinical and clinical development. For more information, please visit www.labopharm.com.

Contact Information

480 Armand-Frappier Boulevard
Laval, QCH7V4B4

tel: 450-686-1017
fax: 450-686-9141


Investor Relations



Exchange: NASDAQ
Industry: Drug Related Products
Market Cap: $102.8M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.